Barclays analyst Etzer Darout initiated coverage of Scholar Rock (SRRK) with an Overweight rating and $45 price target The company’s lead asset, apitegromab, is an anti-latent myostatin antibody that has successfully completed a Phase 3 trial in spinal muscular atrophy, and a U.S. FDA approval decision is expected in September 2025, the analyst tells investors in a research note. Scholar Rock’s R&D pipeline also includes SRK-439, an anti-latent myostatin, that the company plans to submit an IND for exploration in rare neuromuscular disorders in the second half of 2025, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock initiated with an Overweight at Barclays
- Scholar Rock initiated with an Outperform at Leerink
- Scholar Rock assumed with a Buy at Jefferies
- Scholar Rock publishes SAPPHIRE trial data in The Lancet
- Positive Outlook on Scholar Rock Holdings Due to Innovative Therapies and Strategic Advancements